ES3062289T3 - Factor xiia inhibitors - Google Patents

Factor xiia inhibitors

Info

Publication number
ES3062289T3
ES3062289T3 ES19721369T ES19721369T ES3062289T3 ES 3062289 T3 ES3062289 T3 ES 3062289T3 ES 19721369 T ES19721369 T ES 19721369T ES 19721369 T ES19721369 T ES 19721369T ES 3062289 T3 ES3062289 T3 ES 3062289T3
Authority
ES
Spain
Prior art keywords
factor xiia
xiia inhibitors
inhibitors
factor
xiia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19721369T
Other languages
Spanish (es)
Inventor
Helen Philippou
Richard Foster
Colin Fishwick
Charlotte Revill
Ian Yule
Roger Taylor
Alan Naylor
Philip Spencer Fallon
Stuart Crosby
Anna Hopkins
Mark Richard Stewart
Natalie Louise Winfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
University of Leeds Innovations Ltd
Original Assignee
University of Leeds
University of Leeds Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds, University of Leeds Innovations Ltd filed Critical University of Leeds
Application granted granted Critical
Publication of ES3062289T3 publication Critical patent/ES3062289T3/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES19721369T 2018-04-30 2019-04-29 Factor xiia inhibitors Active ES3062289T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1807014.4A GB201807014D0 (en) 2018-04-30 2018-04-30 Factor xlla inhibitors
PCT/GB2019/051180 WO2019211585A1 (en) 2018-04-30 2019-04-29 FACTOR XIIa INHIBITORS

Publications (1)

Publication Number Publication Date
ES3062289T3 true ES3062289T3 (en) 2026-04-09

Family

ID=62495146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19721369T Active ES3062289T3 (en) 2018-04-30 2019-04-29 Factor xiia inhibitors

Country Status (10)

Country Link
US (1) US20210087172A1 (en)
EP (1) EP3788039B1 (en)
JP (1) JP2021523887A (en)
KR (1) KR20210005629A (en)
CN (1) CN112204023A (en)
AU (1) AU2019264253B2 (en)
CA (1) CA3097811A1 (en)
ES (1) ES3062289T3 (en)
GB (1) GB201807014D0 (en)
WO (1) WO2019211585A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
CN112867706B (en) 2018-05-29 2024-11-15 奥默罗斯公司 MASP-2 inhibitors and methods of use
KR20210067005A (en) * 2019-11-28 2021-06-08 제이투에이치바이오텍 (주) Prodrug compounds of edaravone and their medical use for treating or alleviating neurodegenerative or motor neuron diseases
EP4069676A1 (en) * 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
JP7699389B2 (en) 2019-12-04 2025-06-27 オメロス コーポレーション MASP-2 inhibitors and methods of use
IL293550A (en) * 2019-12-04 2022-08-01 Omeros Corp Masp-2 inhibitor compounds, compositions comprising same and uses thereof
BR112022010881A2 (en) 2019-12-04 2022-08-23 Omeros Corp COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD TO TREAT A DISEASE OR DISORDER ASSOCIATED WITH SERINE PROTEASE-2 ASSOCIATED WITH MANAN-BINDING LECTIN
JP2023552747A (en) 2020-12-01 2023-12-19 カルビスタ・ファーマシューティカルズ・リミテッド enzyme inhibitor
JP2023554346A (en) 2020-12-18 2023-12-27 アイオーニス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for modulating factor XII
TW202302565A (en) 2021-02-19 2023-01-16 英商卡爾維斯塔製藥有限公司 Enzyme inhibitors
TW202412765A (en) 2022-08-18 2024-04-01 英商卡爾維斯塔製藥有限公司 Enzyme inhibitors
TW202425999A (en) 2022-10-19 2024-07-01 英商卡爾維斯塔製藥有限公司 Enzyme inhibitors
WO2024218503A1 (en) 2023-04-20 2024-10-24 Kalvista Pharmaceuticals Limited Solid forms of an enzyme inhibitor and salts thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
AU709088B2 (en) * 1995-10-24 1999-08-19 Merck & Co., Inc. Thrombin inhibitors
CA2200163A1 (en) * 1996-03-22 1997-09-22 Michael Robert Wiley Antithrombotic diamides
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them
DE69921358T2 (en) 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. NITROGENIC HETEROBICYCLES AS FACTOR XA HEMMER
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
EP2655399B1 (en) * 2010-12-21 2017-09-27 The Medicines Company (Leipzig) GmbH Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa
WO2018093695A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS

Also Published As

Publication number Publication date
EP3788039A1 (en) 2021-03-10
CA3097811A1 (en) 2019-11-07
EP3788039B1 (en) 2026-02-11
AU2019264253B2 (en) 2023-02-23
CN112204023A (en) 2021-01-08
KR20210005629A (en) 2021-01-14
JP2021523887A (en) 2021-09-09
US20210087172A1 (en) 2021-03-25
EP3788039C0 (en) 2026-02-11
AU2019264253A1 (en) 2020-11-19
GB201807014D0 (en) 2018-06-13
WO2019211585A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
SG11202106520VA (en) Kif18a inhibitors
ES3062289T3 (en) Factor xiia inhibitors
IL277006A (en) Cd73 inhibitors
ZA201905811B (en) Novel inhibitors
IL304348A (en) Cd73 inhibitors
ZA202107835B (en) Prc2 inhibitors
ZA201907136B (en) Ip6k inhibitors
SG11202010347XA (en) Stat3 inhibitors
IL276013A (en) Pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL283112A (en) Lox inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
EP3833374C0 (en) PROTEASOMIC INHIBITORS
GB201809295D0 (en) Lox inhibitors
GB2578396B (en) Amidodiamine corrosion inhibitors
GB201721465D0 (en) Inhibitors
HK40044877A (en) Factor xiia inhibitors
GB201812462D0 (en) Inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201809939D0 (en) Eastase inhibitor
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors